ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $552,289 | +48.2% | 5,898 | +41.3% | 0.26% | +50.6% |
| Q2 2023 | $372,619 | -52.6% | 4,175 | -43.1% | 0.17% | -73.5% |
| Q1 2023 | $786,780 | -12.2% | 7,338 | 0.0% | 0.64% | +20.5% |
| Q4 2022 | $896,190 | -11.3% | 7,338 | -25.0% | 0.53% | -7.8% |
| Q3 2022 | $1,010,000 | +46.0% | 9,780 | +31.4% | 0.58% | +38.0% |
| Q2 2022 | $692,000 | -24.6% | 7,442 | -4.8% | 0.42% | -28.4% |
| Q1 2022 | $918,000 | -20.1% | 7,821 | -8.4% | 0.58% | -36.2% |
| Q4 2021 | $1,149,000 | -26.2% | 8,541 | -12.6% | 0.92% | -11.2% |
| Q3 2021 | $1,557,000 | +95.4% | 9,769 | +61.2% | 1.03% | +82.3% |
| Q2 2021 | $797,000 | +12.4% | 6,060 | +10.1% | 0.56% | +7.2% |
| Q1 2021 | $709,000 | -10.1% | 5,505 | +16.4% | 0.53% | +4.6% |
| Q4 2020 | $789,000 | +54.7% | 4,731 | +43.1% | 0.50% | +35.5% |
| Q3 2020 | $510,000 | +19.2% | 3,307 | +14.3% | 0.37% | +5.1% |
| Q2 2020 | $428,000 | – | 2,893 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |